Turning the power of nuclear technology into a medical force
Not your grandparents’ nuclear medicine
About Advanced Accelerator Applications
1 of the 4
platforms of the Novartis Bold4Cure strategy
Founded in 2002, AAA has a strong legacy as a pioneer in nuclear medicine.
We believe targeted radioligand therapy has the potential to be broadly used in many different tumor types.
“This is a very exciting time in AAA’s development. I believe in the potential of radioligand therapy to transform patients’ lives and I am committed to exploring this therapeutic approach in multiple tumor types.”
President of AAA